BeyondSpring (NASDAQ:BYSI) has been assigned a $60.00 target price by HC Wainwright in a report released on Monday. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 89.93% from the company’s current price.
Other analysts also recently issued research reports about the company. Maxim Group reiterated a “buy” rating and issued a $52.00 price objective on shares of BeyondSpring in a research report on Friday, October 27th. Zacks Investment Research downgraded BeyondSpring from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. BeyondSpring currently has an average rating of “Buy” and a consensus price target of $54.50.
Shares of BeyondSpring (NASDAQ BYSI) opened at $31.59 on Monday. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49.
A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. bought a new position in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up about 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring at the end of the most recent reporting period. Institutional investors own 1.22% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “BeyondSpring (BYSI) Given a $60.00 Price Target by HC Wainwright Analysts” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/12/06/beyondspring-bysi-given-a-60-00-price-target-by-hc-wainwright-analysts.html.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.